BioCentury | Nov 15, 2010
Clinical News

NX001: Phase I started

...in healthy volunteers. The compound has Orphan Drug designation in the U.S. for the indication. NephRx Corp....
BioCentury | Oct 25, 2010
Clinical News

NephRx preclinical data

...saline-treated controls (p=0.001). NX002 is a peptide derived from the gastric growth factor AMP-18 . NephRx Corp....
BioCentury | Aug 23, 2010
Clinical News

NX001 regulatory update

...FDA granted Orphan Drug designation for NephRx's NX001 to prevent delayed graft function in renal transplant...
...peptide is in preclinical development with Phase I testing expected to begin by year end. NephRx Corp....
BioCentury | Jun 25, 2009
Strategy

Science for export

...Not available Midway Pharmaceuticals Inc. Therapeutics for GI tract diseases 2005 Spring House, Pa. $500K NephRx Corp....
Items per page:
1 - 4 of 4
BioCentury | Nov 15, 2010
Clinical News

NX001: Phase I started

...in healthy volunteers. The compound has Orphan Drug designation in the U.S. for the indication. NephRx Corp....
BioCentury | Oct 25, 2010
Clinical News

NephRx preclinical data

...saline-treated controls (p=0.001). NX002 is a peptide derived from the gastric growth factor AMP-18 . NephRx Corp....
BioCentury | Aug 23, 2010
Clinical News

NX001 regulatory update

...FDA granted Orphan Drug designation for NephRx's NX001 to prevent delayed graft function in renal transplant...
...peptide is in preclinical development with Phase I testing expected to begin by year end. NephRx Corp....
BioCentury | Jun 25, 2009
Strategy

Science for export

...Not available Midway Pharmaceuticals Inc. Therapeutics for GI tract diseases 2005 Spring House, Pa. $500K NephRx Corp....
Items per page:
1 - 4 of 4